What the 2027 ICD-10 updates mean for lab test orders and medical necessity

Most coverage of the annual ICD-10 update is written for coders and billers deciding how to sequence a claim.

For a lab, the more useful question is different: does the diagnosis code on this requisition actually support the test being ordered?

When it doesn't, the result is a medical necessity denial—and several of this year's new codes affect this directly, particularly for molecular, toxicology, and microbiology testing.

Payers use local and national coverage determinations to define which diagnosis codes justify which tests. A requisition carrying a vague or outdated code, when a more specific one now exists, is a common and avoidable source of denial.

Every October, that list of "more specific" options changes—and a lab that hasn't updated its requisition templates or EHR order sets is relying on its ordering physicians to know the new codes on their own, which they usually don't.

The 2027 update added dedicated codes for several hereditary conditions that previously had to be captured with less specific family-history or screening codes:

• Lynch syndrome—QA1.71
• Familial cancer syndrome with pathogenic BRCA1 mutation—QA1.790
• Familial cancer syndrome with pathogenic BRCA2 mutation—QA1.791
• Li-Fraumeni syndrome—QA1.792
• Other inherited neoplasm predisposition syndrome of multiple systems—QA1.798
• Loeys-Dietz syndrome—Q87.A

For a molecular or reference lab running hereditary cancer panels, these codes are directly relevant to whether a claim gets paid without a fight.

A requisition still carrying an older, general "family history of malignant neoplasm" code, when the ordering provider actually means Lynch syndrome or a confirmed BRCA mutation, is more likely to trigger a medical necessity denial than one using the new, condition-specific code.

Flagging this shift for referring providers, rather than waiting to catch it at claims review, is the more effective fix.

For background on these conditions to share with staff or referring offices, the National Cancer Institute's genetics overview and the National Organization for Rare Disorders both maintain clear, non-promotional explanations.

Toxicology labs should take note of two changes in particular. The T52 and T59 ranges were restructured with more specific codes for solvent and industrial-coating exposures, and a new code, T65.85-, was added for medetomidine—a veterinary sedative increasingly found as an additive in illicit fentanyl.

“It's basically a veterinary drug that's being added to illicit fentanyl to mimic the sedative effect,” said Coding Supervisor Brad Sirota, CPC, CPMA, ARIA Health Services.

Because of this, medetomidine is turning up in overdose and emergency drug-screen cases, and a lab running comprehensive toxicology panels should expect to see this code appear on requisitions with more regularity as ordering providers catch up to it.

Getting ahead of it matters for reimbursement: a drug screen ordered against a generic "poisoning by unspecified drug" code is a weaker claim than one tied to the specific substance actually being tested for, and coverage policies are increasingly written around that level of specificity.

The musculoskeletal chapter added more than 30 new codes this year, most of them expanding the "other osteomyelitis" category (M86.8X-) with laterality and specific body-site detail—shoulder, upper arm, forearm, hand, thigh, lower leg, ankle and foot, skull, and face and sinuses, each broken out by side.

For a microbiology lab running bone or joint cultures, more specific ordering diagnoses generally support more specific, better-justified culture panels, and give the referring provider less reason to fall back on a vague "osteomyelitis, unspecified" code that doesn't match the actual clinical picture.

Sepsis coding rules didn't change this year, but they're worth a mention here because labs run the tests—blood cultures, lactate, procalcitonin—that a sepsis diagnosis depends on. 

ICD-10 requires the underlying infectious organism to be coded first, with severe sepsis or septic shock codes sequenced after it, and organ dysfunction codes added when applicable.

When that sequencing is wrong or incomplete on the ordering side, it's not just the practice's claim at risk—the lab's claim for the same encounter can be denied right alongside it, since payers frequently evaluate the full clinical picture rather than each claim in isolation.

A stale diagnosis code sitting in a referring provider's order set or a paper requisition template can lead to denials. A short annual review, timed around the October 1 effective date, of which diagnosis codes appear most often on incoming requisitions for hereditary panels, toxicology screens, and culture orders is usually enough to catch outdated codes before they turn into denials.

Where that review needs to happen depends on how orders actually reach the lab.

Some referring practices are interfaced directly to the lab's EHR; smaller offices may instead route orders through a web-based portal such as CGM LABNEXUS. It's worth confirming, for each referral path your lab relies on, where the diagnosis code list is actually maintained and how current it stays—rather than assuming any one workflow automatically keeps itself up to date.